An open-label extension study to evaluate the long-term safety and tolerability of Lu AE58054 as adjunctive treatment to donepezil in patients with mild-moderate Alzheimer's disease
M
Martin Farlow, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Not Recruiting
100 years and younger
All
Phase
N/A
1 Location
Overview
This study is designed as a classic open-label extension study with add-on design to evaluate the long-term safety and tolerability of Lu AE8054 as adjunctive therapy to donepezil in subjects with mild-moderate Alzheimer?s disease (AD).
Description
This study is designed as a classic open-label extension study with add-on design to evaluate the long-term safety and tolerability of Lu AE8054 as adjunctive therapy to donepezil in subjects with mild-moderate Alzheimer?s disease (AD).
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Alzheimer's disease
-
Age: - 100 Years
-
Gender: All
Updated on
12 May 2024.
Study ID: 1404753701